The global gene expression market size was valued at USD 9.07 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 9.96% from 2021 to 2028. The development of technologically advanced solutions is anticipated to provide growth avenues to this market. For instance, in May 2020, 10x Genomics, Inc. launched 10x-targeted single-cell RNA sequencing, the company’s targeted gene expression solution for spatial genomics and single-cell analysis. This product can efficiently analyze a subset of genes of interest. Therefore, it reduces the computational & sequencing burden, streamlines data analysis, and increases sample throughput. Moreover, rise in gene exp. studies to analyze the COVID-19-risk variants are expected to drive the global market.
In December 2020, a team of researchers from the University of Liverpool, U.K., and University of California used the Database of Immune Cell Expression, Expression quantitative trait loci (eQTLs), and Epigenomics (DICE) to conduct gene exp. studies in different types of immune cells, which are affected by genetic variations related to COVID-19 severity.
Gene exp. has emerged as one of the key technologies used in various applications, such as drug discovery and development procedures, clinical diagnostics, biotechnology, microbiology, and others. The adoption of this technique across various stages of the drug discovery process has increased in recent years. Limitations in the usage of existing technologies along with the expanding scope of application for gene exp. analysis has accelerated the development of novel approaches.
For instance, hybridization-based detection and the use of predesigned oligonucleotide probes limit the use of microarrays during drug development. The advent of Cap Analysis of Gene Exp. (CAGE) has helped to overcome this as it facilitates comprehensive mapping of promoters and starts sites of human transcription. The technique also permits mRNA quantification in cells.
The cDNA synthesis & conversion process segment led the market with a revenue share of 27.06% in 2020 owing to the availability of a wide range of kits for cDNA synthesis to match the research needs pertaining to optimal reaction temperature, the number of reactions, and sample size. In addition, a rise in product launches of cDNA synthesis and library preparation kits is anticipated to propel the segment growth.
For instance, in February 2021, SeqWell launched the plexWell Single Cell Rapid Kit for the preparation of libraries for single-cell RNA sequencing. The product has brought significant enhancements to the Smart-seq2 method, which involves amplification and synthesis of cDNA. It also helps in the reduction of normalization and quality control burden by 75%.
The data analysis & interpretation segment is expected to register the fastest CAGR over the forecast period. Companies compete to provide the best data analytics and interpretation results for gene exp. arrays. For instance, in June 2020, Illumina acquired BlueBee, a cloud-based software company, to enhance Illumina’s capabilities for interpretation and analysis of data delivered by its sequencing systems.
High investments in cancer-related research and the need for better interpretation software for cancer gene exp. would accelerate the segment growth. Various approaches and algorithms are developed focusing on gene exp. studies for such complex diseases. For instance, projective clustering techniques and ensemble techniques are reported to be used for the integration of cancer gene exp. data.
The kits & reagents product segment dominated the global gene expression market in 2020 with a revenue share of over 74%. The large share of the segment is attributed to the presence of a high number of companies offering different types of kits & reagents for gene exp. For instance, Agilent Technologies, Inc. offers an extensive range of gene exp. microarray kits & reagents. Furthermore, the introduction of advanced products designed for specific applications drives the segment growth.
In May 2020, CARTANA, a biotechnology company based in Sweden, launched a range of in situ sequencing kits to perform high-throughput mapping in single cells. This product is 5 to 10 times more sensitive than the company’s cDNA-based kits. Therefore, the launch of such products increases the utilization of kits & reagents.
The DNA chip/microarray segment is estimated to register the fastest CAGR from 2021 to 2028 owing to the rise in utilization of DNA microarrays for analysis of gene exp. Microarrays facilitate high-throughput gene exp. analysis of large genome sets. Moreover, technological advancements in this area have increased the application of microarrays in diagnostics, drug discovery, biomedicine, and other biotechnology fields.
The High-Plex capacity segment accounted for the largest revenue share of 64.2% in 2020 and is projected to retain the dominant position by growing at the fastest CAGR over the forecast period. A rise in the adoption of gene exp. analysis for multiple genomic studies is a key factor driving the segment growth. Moreover, the presence of market participants, such as ThermoFisher Scientific, that offer high-throughput and fast solutions for multiplexed gene exp. quantitation boosts the segment development.
For instance, Illumina, Inc. offers TruSeq Targeted RNA Exp. Library Prep Kits for customized mid- to high-plex profiling. Furthermore, high-plex analysis reduces hands-on time when compared to qPCR and other conventional technologies. The technique is also highly accurate and simple as it eliminates the requirement of upfront probe validation. The development of spatially resolved, multiplexed digital characterization systems further enhances the segment growth.
The RNA exp. technique segment dominated the market with a revenue share of over 41% in 2020. Acceleration of high-throughput technologies, such as cDNA microarray and RNA sequencing (RNA-seq), often replaces preceding techniques. Hence, technological advances in RNA exp. tools and techniques coupled with the availability of a range of products to meet different research needs are anticipated to increase the adoption of these techniques for gene exp. analysis.
DNA microarrays and PCR techniques are the major contributors to the large share of this segment as these techniques have a significant adoption rate and have helped researchers and biologists to study expressions of various genes and microorganisms. Microarrays are used to obtain wide coverage of genome expression. Thus, increased genomic research that studies the effects of mutation in biological systems or investigates changes in exp. profiling of the whole genome is anticipated to increase the adoption of DNA microarrays.
RT-PCR has brought revolutionary changes to gene exp. studies with its high efficiency and speed. Moreover, advanced versions of PCR, such as digital PCR and qPCR, have applications in differential or comparative exp. analysis. These improvements in the PCR technology have increased the adoption of PCR for RNA exp. analysis.
The drug discovery & development segment accounted for the largest revenue share of over 41% in 2020. A rise in the analysis of gene exp. profiles of SARS-CoV-2 receptors for in silico drug discovery for COVID-19 is a high-impact rendering driver for the segment. An August 2020 research study used gene exp. profiles to explore major functions of Angiotensin-converting enzyme 2 (ACE2)-correlated genes.
Gene exp. profiles were obtained from Genotype-Tissue Exp., Gene Exp. Omnibus, The Cancer Genome Atlas, and other public datasets. As ACE2 is the main cell receptor for SARS-CoV-2 and SARS-CoV, such type of co-expression analysis helped with the evaluation of drugs for Covid-19 treatment.
A rise in demand for early and accurate diagnostic tests for complex disorders is expected to drive the clinical diagnostics application segment with the fastest CAGR from 2021 to 2028. The use of RNA exp. in clinical diagnostics to provide an early and accurate diagnosis of the Early-Onset Infection (EOI) and other rare genetic conditions in preterm infants drives segment growth.
North America held the largest revenue share of more than 45% in 2020. This can be attributed to the presence of a significant number of key players, such as Thermo Fisher Scientific, in the region.
Key players are continuously involved in extensive R&D to develop new technology & methods that involve gene exp. analysis. For instance, Decibel Therapeutics, Inc., a U.S.-based biotechnology company, collaborated with Regeneron Pharmaceuticals to develop DB-OTO. DB-OTO is a preclinical stage gene therapy candidate that is being developed by using an exclusive, cell-selective promoter to regulate gene exp. in hair cells of the cochlea. The product is expected to enter the clinical phase by 2022.
Asia Pacific is estimated to be the fastest-growing regional market from 2021 to 2028 owing to the rising interest of dominant players in emerging markets, such as China and India. Sequencing and array technologies are widely adopted in this region owing to increased genomic and gene-related studies. Japan maintains its data repositories, such as DNA Data Bank of Japan (DDBJ) and Kyoto Encyclopedia of Genes and Genomes. These provide tools, such as GenomeNet Bioinformatics Tools, for sequencing, genome, and chemical analysis.
Most of the market leaders follow organic growth strategies to reinforce their market presence. For instance, in September 2020, 10x Genomics commercialized its Chromium Single Cell Multiome ATAC + Gene Expression solutions. In March 2020, Thermo Fisher Scientific, Inc. launched the PowerTrack SYBR Green PCR Master Mix for real-time PCR workflow to amplify targets for precise gene exp. analysis. Some of the prominent players in the global gene expression market include:
Quest Diagnostics, Inc.
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
Takara Bio, Inc.
Interpace Biosciences, Inc.
Market size value in 2021
USD 10.14 billion
Revenue forecast in 2028
USD 19.40 billion
CAGR of 9.96% from 2021 to 2028
Base year for estimation
2017 - 2019
2021 - 2028
Revenue in USD million/billion and CAGR from 2021 to 2028
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Process, product, capacity, technique, application, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; Germany; France; U.K.; Italy; Spain; China; Japan; India; Australia; South Korea; Brazil; Mexico; South Africa; Saudi Arabia
Key companies profiled
QIAGEN; Quest Diagnostics, Inc.; F. Hoffmann-La Roche Ltd.; Illumina, Inc.; PerkinElmer, Inc.; Bio-Rad Laboratories; Thermo Fisher Scientific, Inc.; Agilent Technologies; GE Healthcare; Promega Corp.; Luminex Corp.; Takara Bio, Inc.; Danaher Corp.; ELITechGroup; AutoGenomics; Biocartis NV; IntegraGen; Interpace Biosciences, Inc.; Fluidigm Corp.
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global gene expression market report on the basis of process, product, capacity, technique, application, and region:
Process Outlook (Revenue, USD Million, 2017 - 2028)
cDNA Synthesis & Conversion
Data Analysis & Interpretation
Product Outlook (Revenue, USD Million, 2017 - 2028)
Kits & Reagents
Capacity Outlook (Revenue, USD Million, 2017 - 2028)
Low- to Mid-Plex
Technique Outlook (Revenue, USD Million, 2017 - 2028)
In vitro Transcription/Nuclear Run-On Assays
Gel Shift Assays
Chromatin Immunoprecipitation (ChIP) Assays
Protein Exp. & Posttranslational Modification Analysis
2-D Gel Electrophoresis
Application Outlook (Revenue, USD Million, 2017 - 2028)
Drug Discovery & Development
Biotechnology & Microbiology
Regional Outlook (Revenue, USD Million, 2017 - 2028)
Middle East Africa (MEA)
b. The global gene expression market size was estimated at USD 9.08 billion in 2020 and is expected to reach USD 10.14 billion in 2021.
b. The global gene expression market is expected to grow at a compound annual growth rate of 9.96% from 2021 to 2028 to reach USD 19.41 billion by 2028.
b. Kits & reagents dominated the gene expression market with a share of 74.3% in 2020. This is attributable to the high penetration of kits and reagents in the space in terms of product availability, usage rate, and purchase frequency.
b. Some key players operating in the gene expression market include QIAGEN, Quest Diagnostics Incorporated, F. Hoffmann-La Roche Ltd, Illumina, Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Agilent Technologies, GE Healthcare, and TAKARA BIO INC.
b. Key factors that are driving the gene expression market growth include increasing interest of research entities in transcriptomic profiling coupled with technological advancements in genomic technologies in terms of accuracy, specificity, and outcome.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.